These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36261273)

  • 1. Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses.
    Fields A; Potel KN; Cabuhal R; Aziri B; Stewart ID; Schock BC
    Thorax; 2023 Aug; 78(8):799-807. PubMed ID: 36261273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease.
    Györfi AH; Filla T; Dickel N; Möller F; Li YN; Bergmann C; Matei AE; Harrer T; Kunz M; Schett G; Distler JHW
    Rheumatology (Oxford); 2024 Apr; 63(4):962-969. PubMed ID: 37421394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
    Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
    Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
    Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM
    Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
    Schmidt K; Martinez-Gamboa L; Meier S; Witt C; Meisel C; Hanitsch LG; Becker MO; Huscher D; Burmester GR; Riemekasten G
    Arthritis Res Ther; 2009; 11(4):R111. PubMed ID: 19615053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study.
    Jee AS; Stewart I; Youssef P; Adelstein S; Lai D; Hua S; Stevens W; Proudman S; Ngian GS; Glaspole IN; Moodley YP; Bleasel JF; Macansh S; Nikpour M; Sahhar J; Corte TJ;
    Arthritis Rheumatol; 2023 Aug; 75(8):1424-1433. PubMed ID: 36908055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
    Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].
    Hua-Huy T; Rivière S; Tiev KP; Dinh-Xuan AT
    Rev Pneumol Clin; 2014 Dec; 70(6):335-42. PubMed ID: 25457218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.
    Petelytska L; Bonomi F; Cannistrà C; Fiorentini E; Peretti S; Torracchi S; Bernardini P; Coccia C; De Luca R; Economou A; Levani J; Matucci-Cerinic M; Distler O; Bruni C
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37940340
    [No Abstract]   [Full Text] [Related]  

  • 12. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
    Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
    J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature.
    Kowal-Bielecka O; Kowal K; Highland KB; Silver RM
    Semin Arthritis Rheum; 2010 Aug; 40(1):73-88. PubMed ID: 19152959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.
    Bonhomme O; André B; Gester F; de Seny D; Moermans C; Struman I; Louis R; Malaise M; Guiot J
    Rheumatology (Oxford); 2019 Sep; 58(9):1534-1546. PubMed ID: 31292645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
    Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
    Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
    Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-Selectin, ICAM-1, and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases.
    Pulito-Cueto V; Remuzgo-Martínez S; Genre F; Atienza-Mateo B; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Mora-Gil MS; Portilla V; Corrales A; Blanco R; Cifrián JM; González-Gay MA; López-Mejías R
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis.
    Sfriso P; Cozzi F; Oliviero F; Caso F; Cardarelli S; Facco M; Fittà C; Del Rosso A; Matucci-Cerinic M; Punzi L; Agostini C
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S71-5. PubMed ID: 22691213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.